AK104/Tislelizumab
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for AK104/Tislelizumab, covering 2023-08-14 to 2023-08-14. Get the full timeline:
Most recent: Clinical Trial Update: A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer [Phase 3]